Gary Lyman, MD, MPH, of the Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance, discusses how biosimilar granulocyte colony-stimulating factor (G-CSF) therapies have impacted cancer care.
Transcript
Again, we're very early. The first biosimilar [granulocyte colony-stimulating factor, G-CSF] was approved just in recent years. We now have another biosimilar that was approved as an originator, tbo-filgrastim, and 2 true biosimilars in the [United States], the forms of filgrastim, and now just over the last few months approval of the long-acting filgrastim, pegfilgrastim, which has been available in Europe but now is also available in the [United States].
But this is brand new data. In fact, in many institutions, it isn’t even available yet as the drug gets distributed. So the only data that we have is from the filgrastim originator versus the filgrastim-sndz, which was approved a couple of years ago, and the data there suggest there's been rapid uptake of the biosimilar filgrastim; at least half, maybe two-thirds of the utilization of G-CSF in the United States has switched from the original drug to the biosimilar.
The impact on cost is more challenging, and again very preliminary data. But as I alluded to, perhaps showing around a 10% the 12% decrease in price over the first year or 2 of the use of the biosimilars.
One will expect (again, in Europe, they’ve seen this) with time and with more and more competition, more and more biosimilars, there will be further reductions in pricing, perhaps to the extent of a 20% to 30% decrease.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.